Search Results - "Von Schumann, Raquel"

De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR–): survival outcomes from a multicentre, open-label, randomised, phase 2 trial by Nitz, Ulrike, Gluz, Oleg, Graeser, Monika, Christgen, Matthias, Kuemmel, Sherko, Grischke, Eva-Maria, Braun, Michael, Augustin, Doris, Potenberg, Jochem, Krauss, Katja, Schumacher, Claudia, Forstbauer, Helmut, Reimer, Toralf, Stefek, Andrea, Fischer, Hans Holger, Pelz, Enrico, zu Eulenburg, Christine, Kates, Ronald, Wuerstlein, Rachel, Kreipe, Hans Heinrich, Harbeck, Nadia, von Schumann, Raquel, Kuhn, Walther, Polata, Silke, Bielecki, Wojciech, Meyer, Ralf, Just, Marianne, Kraudelt, Susanne, Siggelkow, Wulf, Wortelmann, Heidi, Kleine-Tebbe, Anke, Leitzen, Lena, Kirchhof, Heidrun, Krabisch, Petra, Hackmann, John, Depenbusch, Reinhard, Gnauert, Karsten, Staib, Peter, Lehnert, Antje, Hoffmann, Oliver, Briest, Susanne, Lindner, Christoph, Heyl, Volker, Bauer, Leila, Uleer, Christoph, Mohrmann, Svjetlana, Viehstaedt, Nicole, Malter, Wolfram, Link, Theresa, Buendgen, Nana, Tio, Joke

“…Several de-escalation neoadjuvant strategies have been investigated to reduce the use of chemotherapy in HER2-positive early breast cancer using pathological…”
Get full text

Early response by MR imaging and ultrasound as predictor of pathologic complete response to 12‐week neoadjuvant therapy for different early breast cancer subtypes: Combined analysis from the WSG ADAPT subtrials by Graeser, Monika, Schrading, Simone, Gluz, Oleg, Strobel, Kevin, Würstlein, Rachel, Kümmel, Sherko, Schumacher, Claudia, Grischke, Eva‐Maria, Forstbauer, Helmut, Braun, Michael, Christgen, Matthias, Adams, Jascha, Nitzsche, Henrik, Just, Marianne, Fischer, Hans Holger, Aktas, Bahriye, Potenberg, Jochem, Schumann, Raquel, Kolberg‐Liedtke, Cornelia, Harbeck, Nadia, Kuhl, Christiane K., Nitz, Ulrike

“…We evaluated the role of early response after 3 weeks of neoadjuvant treatment (NAT) assessed by ultrasound (US), magnetic resonance imaging (MRI) and Ki‐67…”
Get full text

Magnetic resonance imaging and ultrasound for prediction of residual tumor size in early breast cancer within the ADAPT subtrials by Graeser, Monika, Schrading, Simone, Gluz, Oleg, Strobel, Kevin, Herzog, Christopher, Umutlu, Lale, Frydrychowicz, Alex, Rjosk-Dendorfer, Dorothea, Würstlein, Rachel, Culemann, Ralph, Eulenburg, Christine, Adams, Jascha, Nitzsche, Henrik, Prange, Anna, Kümmel, Sherko, Grischke, Eva-Maria, Forstbauer, Helmut, Braun, Michael, Potenberg, Jochem, von Schumann, Raquel, Aktas, Bahriye, Kolberg-Liedtke, Cornelia, Harbeck, Nadia, Kuhl, Christiane K, Nitz, Ulrike

“…Prediction of histological tumor size by post-neoadjuvant therapy (NAT) ultrasound and magnetic resonance imaging (MRI) was evaluated in different breast…”
Get full text

Immune Markers and Tumor-Related Processes Predict Neoadjuvant Therapy Response in the WSG-ADAPT HER2-Positive/Hormone Receptor-Positive Trial in Early Breast Cancer by Harbeck, Nadia, von Schumann, Raquel, Kates, Ronald Ernest, Braun, Michael, Kuemmel, Sherko, Schumacher, Claudia, Potenberg, Jochem, Malter, Wolfram, Augustin, Doris, Aktas, Bahriye, Forstbauer, Helmut, Tio, Joke, Grischke, Eva-Maria, Biehl, Claudia, Liedtke, Cornelia, De Haas, Sanne Lysbet, Deurloo, Regula, Wuerstlein, Rachel, Kreipe, Hans Heinrich, Gluz, Oleg

“…Prognostic or predictive biomarkers in HER2-positive early breast cancer (EBC) may inform treatment optimization. The ADAPT HER2-positive/hormone…”
Get full text

The use of breast ultrasound for prediction of pathologic complete response in different subtypes of early breast cancer within the WSG-ADAPT subtrials by Graeser, Monika, Harbeck, Nadia, Gluz, Oleg, Würstlein, Rachel, zu Eulenburg, Christine, Schumacher, Claudia, Grischke, Eva-Maria, Forstbauer, Helmut, Dimpfl, Moritz, Braun, Michael, Christgen, Matthias, Kreipe, Hans Heinrich, Potenberg, Jochem, von Schumann, Raquel, Aktas, Bahriye, Kolberg-Liedtke, Cornelia, Kümmel, Sherko, Nitz, Ulrike

“…We assessed the value of breast ultrasound (US) performed at week 3 and 6 and at the end (EOT) of neoadjuvant therapy (NAT) for prediction of pathologic…”
Get full text

Protroca: A Noninterventional Study on Prophylactic Lipegfilgrastim against Chemotherapy-Induced Neutropenia in Nonselected Breast Cancer Patients by Wuerstlein, Rachel, Harbeck, Nadia, Grischke, Eva-Maria, Forstmeyer, Dirk, von Schumann, Raquel, Krabisch, Petra, Lüdtke-Heckenkamp, Kerstin, Stefek, Andrea, Stoetzer, Oliver, Grafe, Andrea, Kaltenecker, Gabriele, Forstbauer, Helmut, Augustin, Doris, Schrader, Iris, Tio, Joke, Nitz, Ulrike, Gluz, Oleg, Kates, Ronald E., Graeser, Monika Karla

“…Background: Protroca evaluated the efficacy and safety of primary and secondary prophylaxis of neutropenia with lipegfilgrastim (Lonquex®) in breast cancer…”
Get full text

De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab P by Harbeck, Nadia, Gluz, Oleg, Christgen, Matthias, Kates, Ronald Ernest, Braun, Michael, Küemmel, Sherko, Schumacher, Claudia, Potenberg, Jochem, Kraemer, Stefan, Kleine-Tebbe, Anke, Augustin, Doris, Aktas, Bahriye, Forstbauer, Helmut, Tio, Joke, von Schumann, Raquel, Liedtke, Cornelia, Grischke, Eva-Maria, Schumacher, Johannes, Wuerstlein, Rachel, Kreipe, Hans Heinrich, Nitz, Ulrike Anneliese

“…Purpose Human epidermal growth factor receptor 2 (HER2)-positive/hormone receptor (HR)-positive breast cancer is a distinct subgroup associated with lower…”
Get full text

Neoadjuvant dynamic marker-adjusted personalized therapy comparing trastuzumab-deruxtecan versus pacli-/docetaxel + carboplatin + trastuzumab + pertuzumab in HER2+ early breast cancer: WSG-ADAPT-HER2-IV by Harbeck, Nadia, Braun, Michael, Gluz, Oleg, Schmid, Peter, Graeser, Monika Karla, Hartkopf, Andreas D., Hoffmann, Oliver, Kostara, Athina, Polata, Silke, Volmer, Lea Louise, von Schumann, Raquel, Wetzig, Sarah, Wiebe, Stefanie, Zaiss, Matthias R., Fischer, Lotta Ada, Scheffen, Iris, Christgen, Matthias, Kreipe, Hans Heinrich, Nitz, Ulrike, Kuemmel, Sherko

“…TPS631 Background: In HER2+ early breast cancer (EBC), combination of standard chemotherapy (CTx) with anti-HER2-antibodies has shown higher efficacy versus…”
Get full text

Abstract P2-16-05: Efficacy of response- and toxicity-guided neoadjuvant chemotherapy in elderly early breast cancer patients: Results of WSG ADAPT elderly sub-trial by Kuemmel, Sherko, Gluz, Oleg, Christgen, Matthias, Potenberg, Jochem, Hackmann, John, von Schumann, Raquel, Graeser, Monika, Mangold, Marina, Wuerstlein, Rachel, Kates, Ronald, Kreipe, Hans H., Nitz, Ulrike, Harbeck, Nadia

“…Introduction: More than 1/3 of early breast cancers (EBC) are diagnosed in women ≥ 70 years. Although polychemotherapy has been shown to be more effective than…”
Get full text

De-Escalated Neoadjuvant Trastuzumab-Emtansine With or Without Endocrine Therapy Versus Trastuzumab With Endocrine Therapy in HR+/HER2+ Early Breast Cancer: 5-Year Survival in the WSG-ADAPT-TP Trial by Harbeck, Nadia, Nitz, Ulrike A, Christgen, Matthias, Kümmel, Sherko, Braun, Michael, Schumacher, Claudia, Potenberg, Jochem, Tio, Joke, Aktas, Bahriye, Forstbauer, Helmut, Grischke, Eva-Maria, Scheffen, Iris, Malter, Wolfram, von Schumann, Raquel, Just, Marianne, Zu Eulenburg, Christine, Biehl, Claudia, Kolberg-Liedtke, Cornelia, Deurloo, Regula, de Haas, Sanne, Jóźwiak, Katarzyna, Hauptmann, Michael, Kates, Ronald, Graeser, Monika, Wuerstlein, Rachel, Kreipe, Hans H, Gluz, Oleg

“…Neoadjuvant chemotherapy is standard of care in human epidermal growth factor receptor 2-positive (HER2+) early breast cancer (EBC), irrespective of the…”
Get full text

De-escalated chemotherapy versus endocrine therapy plus pertuzumab+ trastuzumab for HR+/HER2+ early breast cancer (BC): First efficacy results from the neoadjuvant WSG-TP-II study by Gluz, Oleg, Nitz, Ulrike, Christgen, Matthias, Kuemmel, Sherko, Holtschmidt, Johannes, Priel, Jan, Hartkopf, Andreas, Potenberg, Jochem, Luedtke-Heckenkamp, Kerstin, Just, Marianne, Wuelfing, Pia, von Schumann, Raquel, Graeser, Monika, Wuerstlein, Rachel, Kates, Ronald E., Kreipe, Hans Heinrich, Harbeck, Nadia

“…Abstract only 515 Background: HR+/HER2+ breast cancer (BC) is a distinct entity associated with better prognosis compared to HR-/HER2+ BC. However, combination…”
Get full text

Abstract GS4-03: Neoadjuvant nab-paclitaxel weekly versus dose-dense paclitaxel followed by dose-dense EC in high risk HR+/HER2- early BC by: Results from the neoadjuvant part of ADAPT HR+/HER2- trial by Kuemmel, Sherko, Gluz, Oleg, Nitz, Ulrike, Braun, Michael, Christgen, Matthias, Luedtke-Heckenkamp, Kerstin, von Schumann, Raquel, Darsow, Maren, Forstbauer, Helmut, Potenberg, Jochem, Grischke, Eva-Maria, Aktas, Bahriye, Schumacher, Claudia, Kates, Ronald, Graeser, Monika, Wuerstlein, Rachel, Uleer, Christoph, Hauptmann, Michael, Shak, Steve, Baehner, Rick, Kreipe, Hans, Harbeck, Nadia

“…Background: Pathological complete response (pCR) is associated with improved outcome in patients with high-risk HR+/HER2- breast cancer (BC) but the use of…”
Get full text

Efficacy of Endocrine Therapy Plus Trastuzumab and Pertuzumab vs De-escalated Chemotherapy in Patients with Hormone Receptor-Positive/ERBB2-Positive Early Breast Cancer: The Neoadjuvant WSG-TP-II Randomized Clinical Trial by Gluz, Oleg, Nitz, Ulrike A, Christgen, Matthias, Kuemmel, Sherko, Holtschmidt, Johannes, Schumacher, Johannes, Hartkopf, Andreas, Potenberg, Jochem, Lüedtke-Heckenkamp, Kerstin, Just, Marianne, Schem, Christian, von Schumann, Raquel, Kolberg-Liedtke, Cornelia, Eulenburg, Christine Zu, Schinköthe, Timo, Graeser, Monika, Wuerstlein, Rachel, Kates, Ronald E, Kreipe, Hans Heinrich, Harbeck, Nadia

“…Combination of chemotherapy with (dual) ERBB2 blockade is considered standard in hormone receptor (HR)-positive/ERBB2-positive early breast cancer (EBC)…”
Get more information

Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results by Gluz, Oleg, Nitz, Ulrike, Liedtke, Cornelia, Christgen, Matthias, Grischke, Eva-Maria, Forstbauer, Helmut, Braun, Michael, Warm, Mathias, Hackmann, John, Uleer, Christoph, Aktas, Bahriye, Schumacher, Claudia, Bangemann, Nikola, Lindner, Christoph, Kuemmel, Sherko, Clemens, Michael, Potenberg, Jochem, Staib, Peter, Kohls, Andreas, von Schumann, Raquel, Kates, Ronald, Kates, Ronald, Schumacher, Johannes, Wuerstlein, Rachel, Kreipe, Hans Heinrich, Harbeck, Nadia

“…Abstract Background Pathological complete response (pCR) is associated with improved prognosis in triple-negative breast cancer (TNBC). The optimal…”
Get full text

Abstract PS09-01: Individual patient data meta-analysis of clinical and translational biomarkers for prediction of pathological complete response (pCR) after de-escalated therapy in HER2+ breast cancer in four trials of the West German Study Group by Graeser, Monika, Gluz, Oleg, Eulenburg, Christine zu, Küemmel, Sherko, von Schumann, Raquel, Christgen, Matthias, Wuerstlein, Rachel, Pelz, Enrico, Kreipe, Hans-Heinrich, Schmid, Peter, Thill, Marc, Braun, Michael, Potenberg, Jochem, Schumacher, Claudia, Tio, Joke, Hartkopf, Andreas, Just, Marianne, Schem, Christian, Lüdtke-Heckenkamp, Kerstin, Grischke, Eva-Maria, Hilpert, Felix, Kentsch, Angela, Kates, Ronald, Nitz, Ulrike, Harbeck, Nadia

“…Background Introduction of anti-HER2 therapies substantially improved outcomes for HER2-positive early breast cancer (HER2+ eBC). However, a considerable…”
Get full text

Hormone receptor discordance between local and central pathology with RT-PCR analysis: Results from multicenter Phase III WSG-PlanB trial by Von Schumann, Raquel, Gluz, Oleg, Nitz, Ulrike, Clemens, Michael, Luebbe, Kristina, Aktas, Bahriye, Just, Marianne, Noesselt, Thomas, Henschen, Stephan, Hackmann, John, Lorenz-Salehi, Fatemeh, Freese, Kristin, Svedman, Christer, Kates, Ronald E., Kreipe, Hans Heinrich, Harbeck, Nadia, Liedtke, Cornelia

“…Abstract only…”
Get full text

Abstract OT3-2-04: ADAPT - Adjuvant Dynamic marker-Adjusted Personalized Therapy trial optimizing risk assessment and therapy response prediction in early breast cancer by Nitz, Ulrike, Gluz, Oleg, von Schumann, Raquel, Hofmann, Daniel, Kates, Ronald E, Kuemmel, Sherko, Braun, Michael, Schumacher, Claudia, Nuding, Benno, Aktas, Bahriye, Forstbauer, Helmut, Maass, Nicolai, Rezai, Mahdi, Kraemer, Stefan, Warm, Mathias, Wuerstlein, Rachel, Harbeck, Nadia

“…Background: Early therapy response is currently not regarded for further treatment decisions as standard of care in the treatment of breast cancer (BC)…”
Get full text

Significance of prospective multicenter decision impact WSG-BCIST Study in postmenopausal ER+ HER2- N0 early breast cancer (EBC) for molecular testing for intrinsic subtype definition by Wuerstlein, Rachel, Sotlar, Karl, Gluz, Oleg, Hofmann, Daniel, Otremba, Burkhard, Von Schumann, Raquel, Witzel, Isabelle, Schindlbeck, Christian, Janni, Wolfgang, Schem, Chrisitan, Bauerfeind, Ingo, Hasmueller, Stephan, Tesch, Hans, Paulenz, Axel, Morel, Pascale, Cowens, Wayne, Hornberger, John, Kates, Ronald E., Pelz, Enrico, Harbeck, Nadia

“…Abstract only…”
Get full text